We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

HUTCHMED

FRESCO-2 data support broad uptake in later-line mCRC

Update | 21 September 2022

Arecor Therapeutics

Broadening opportunities and preparing for the future

Update | 21 September 2022

Futura Medical

Interims highlight positive first signs in key markets

Lighthouse | 13 September 2022

Arecor Therapeutics

Key clinical diabetes events on track for H222

Lighthouse | 08 September 2022

HUTCHMED

Rich and diverse pipeline with multiple waves of growth

Update | 06 September 2022

MaxCyte

Strategic investments to support partners & future growth

Update | 06 September 2022

HUTCHMED

On the right track

Outlook | 01 September 2022

Futura Medical

FM71 achieves all primary and secondary endpoints

Lighthouse | 31 August 2022

Arecor Therapeutics

Acquisition of Tetris Pharma and £6m equity raise

Lighthouse | 01 August 2022

ANGLE

£20m raise funds commercialisation through to mid-2024

Lighthouse | 15 July 2022
1 2 3 4 5 6 7 8 9 10 >
322 results found.